ONWARD Medical Announces Publication of Full Year 2023 Financial Results and Business Update Webcast

EINDHOVEN, the Netherlands, April 11, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces that it will publish Full Year 2023 Financial Results and host a webcast to discuss business highlights.

The webcast will be held on April 25, 2024, at 2:00PM CET / 08:00AM ET. It will be hosted by CEO Dave Marver and Interim CFO Khaled Bahi, who will discuss highlights from 2023 and provide a business update.

To join the webcast via Zoom, please register using this link.

Participants may also join by phone:

[phone] (Belgium)

[phone] (Germany)

[phone] (Netherlands)

[phone] (Switzerland)

[phone] (United Kingdom)

[phone] (US)

Additional telephone numbers available

Meeting ID: 869 3710 5839

A recording of the webcast will be available on the Company’s website following the live event.

To learn more about ONWARD Medical’s commitment to partnering with the SCI Community to develop innovative solutions for restoring movement, function, and independence after spinal cord injury, please visit ONWD.com.

*All ONWARD Medical devices and therapies, including but not limited to ARC-IM, ARC-EX, ARC-BCI, and ARC Therapy, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.

About ONWARD Medical  

ONWARD Medical is a medical technology company creating therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and movement disabilities. Building on more than a decade of science and preclinical research conducted at leading neuroscience laboratories, the Company has received ten Breakthrough Device Designations from the US Food and Drug Administration for its ARC Therapy platform.   

ONWARD ARC Therapy, which can be delivered by external ARC-EX or implantable ARC-IM systems, is designed to deliver targeted, programmed spinal cord stimulation. Positive results were presented in 2023 from the Company’s pivotal study, called Up-LIFT, evaluating the ability for transcutaneous ARC Therapy to improve upper extremity strength and function. The Company has submitted its De Novo regulatory application to the FDA for ARC-EX clearance in the US and is preparing for regulatory submission in Europe. In parallel, the Company is conducting studies with its implantable ARC-IM platform, which demonstrated positive interim clinical outcomes for improved blood pressure regulation after SCI. Other ongoing studies include combination use of ARC-IM with a brain-computer interface (BCI) to address multiple symptoms of SCI.